Breaking News

KPRX

Kiora Pharmaceuticals

21
Jun

05/12/23 H.C. Wainwright: Kiora Pharmaceuticals price target raised to $7 from $6 at H.C. Wainwright

03/24/23 H.C. Wainwright: Kiora Pharmaceuticals price target lowered to $6 from $10 at H.C. Wainwright

02/09/23 Maxim: Kiora Pharmaceuticals upgraded to Buy at Maxim after IND approval for KIO-101

02/09/23 Maxim: Kiora Pharmaceuticals upgraded to Buy from Hold at Maxim

Clear This Search Refresh Search

Over a week ago Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
Recommendations	Kiora Pharmaceuticals price target raised to $7 from $6 at H.C. Wainwright » 06:21 05/12/23 05/12 06:21 05/12/23 06:21 KPRX Kiora Pharmaceuticals $2.54 / -0.005 (-0.20%) H.C. Wainwright analyst… H.C. Wainwright analyst Yi Chen raised the firm's price target on Kiora Pharmaceuticals to $7 from $6 and keeps a Buy rating on the shares post the Q1 results. ShowHide Related Items >><< Company News Street Research On The Fly Events KPRX Kiora Pharmaceuticals $2.54 / -0.005 (-0.20%) 02/09/23 Kiora Pharmaceuticals received IND approval for Phase 2 study of KIO-101 01/03/23 Kiora Pharmaceuticals completes enrollment in PCED study for KIO-201 KPRX Kiora Pharmaceuticals $2.54 / -0.005 (-0.20%) 03/24/23 H.C. Wainwright Kiora Pharmaceuticals price target lowered to $6 from $10 at H.C. Wainwright 02/09/23 Maxim Kiora Pharmaceuticals upgraded to Buy at Maxim after IND approval for KIO-101 02/09/23 Maxim Kiora Pharmaceuticals upgraded to Buy from Hold at Maxim 02/07/23 Ladenburg Ladenburg reiterates Buy on Kiora following Phase 2 KIO-101 OPRA+ IND clearance KPRX Kiora Pharmaceuticals $2.54 / -0.005 (-0.20%) 02/09/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/21/23 Kiora Pharmaceuticals Inc
Syndicate	Kiora Pharmaceuticals files to sell common stock, warrants, no amount given » 17:03 05/05/23 05/05 17:03 05/05/23 17:03 KPRX Kiora Pharmaceuticals $2.78 / -0.19 (-6.40%) Ladenburg Thalmann is… Ladenburg Thalmann is acting as sole book-running manager. ShowHide Related Items >><< Company News Street Research On The Fly Events KPRX Kiora Pharmaceuticals $2.78 / -0.19 (-6.40%) 02/09/23 Kiora Pharmaceuticals received IND approval for Phase 2 study of KIO-101 01/03/23 Kiora Pharmaceuticals completes enrollment in PCED study for KIO-201 KPRX Kiora Pharmaceuticals $2.78 / -0.19 (-6.40%) 03/24/23 H.C. Wainwright Kiora Pharmaceuticals price target lowered to $6 from $10 at H.C. Wainwright 02/09/23 Maxim Kiora Pharmaceuticals upgraded to Buy at Maxim after IND approval for KIO-101 02/09/23 Maxim Kiora Pharmaceuticals upgraded to Buy from Hold at Maxim 02/07/23 Ladenburg Ladenburg reiterates Buy on Kiora following Phase 2 KIO-101 OPRA+ IND clearance KPRX Kiora Pharmaceuticals $2.78 / -0.19 (-6.40%) 02/09/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/21/23 Kiora Pharmaceuticals Inc

Over a month ago
Recommendations	Kiora Pharmaceuticals price target lowered to $6 from $10 at H.C. Wainwright » 12:29 03/24/23 03/24 12:29 03/24/23 12:29 KPRX Kiora Pharmaceuticals $3.31 / +0.03 (+0.91%) H.C. Wainwright analyst… H.C. Wainwright analyst Yi Chen lowered the firm's price target on Kiora Pharmaceuticals to $6 from $10 and keeps a Buy rating on the shares post the Q4 results. Assuming 7.2M shares outstanding at the end of 2023, this yields a value of approximately $6, the analyst tells investors in a research note. The firm believes Kiora needs to raise additional capital to fund operations within the next 12 months. ShowHide Related Items >><< Company News Street Research On The Fly KPRX Kiora Pharmaceuticals $3.31 / +0.03 (+0.91%) 02/09/23 Kiora Pharmaceuticals received IND approval for Phase 2 study of KIO-101 01/03/23 Kiora Pharmaceuticals completes enrollment in PCED study for KIO-201 10/18/22 Kiora Pharmaceuticals Inc trading resumes 10/18/22 Kiora Pharmaceuticals Inc trading halted, volatility trading pause KPRX Kiora Pharmaceuticals $3.31 / +0.03 (+0.91%) 02/09/23 Maxim Kiora Pharmaceuticals upgraded to Buy at Maxim after IND approval for KIO-101 02/09/23 Maxim Kiora Pharmaceuticals upgraded to Buy from Hold at Maxim 02/07/23 Ladenburg Ladenburg reiterates Buy on Kiora following Phase 2 KIO-101 OPRA+ IND clearance 01/03/23 Ladenburg Kiora Pharmaceuticals completes enrollment in Phase 2 study, says Ladenburg KPRX Kiora Pharmaceuticals $3.31 / +0.03 (+0.91%) 02/09/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations

Over a quarter ago
On The Fly	Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations » 10:29 02/09/23 02/09 10:29 02/09/23 10:29 NYT New York Times $40.60 / -0.54 (-1.31%) , RPD Rapid7 $53.38 / +1.88 (+3.65%) , DKNG DraftKings $17.73 / +0.06 (+0.34%) , HIMS Hims & Hers $9.55 / +1.12 (+13.29%) , ACCD Accolade $12.50 / -0.1 (-0.79%) , EMKR Emcore $1.35 / +0.035 (+2.66%) , CRNC Cerence $30.32 / +1.43 (+4.95%) , KPRX Kiora Pharmaceuticals $6.82 / -0.1 (-1.45%) , BAC Bank of America $36.16 / -0.355 (-0.97%) , JPM JPMorgan $142.49 / -0.19 (-0.13%) , AFRM Affirm $13.05 / -2.94 (-18.39%) , CPNG Coupang $16.74 / +0.4 (+2.45%) , S SentinelOne $16.20 / +0.455 (+2.89%) , SPWR SunPower $16.04 / -0.225 (-1.38%) , DRCT Direct Digital $5.83 / +0.04 (+0.69%) , VERX Vertex $14.90 / +0.51 (+3.54%) Institutional investors… Open Full Text ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options SPWR S RPD NYT KPRX JPM HIMS EMKR DRCT DKNG CRNC CPNG BAC AFRM ACCD SPWR SunPower $16.04 / -0.225 (-1.38%) 01/10/23 RMI launches virtual power plant partnership with GM, Google, Ford 01/05/23 SunPower, Maxeon Solar extend current supply relationship 11/10/22 California issues revised proposal on rooftop solar subsidies 11/07/22 Notable companies reporting before tomorrow's open S SentinelOne $16.20 / +0.455 (+2.89%) 01/17/23 Crowdstrike adds two executives to its leadership team 01/12/23 SentinelOne selected by JCDC to strengthen U.S. cybersecurity 12/06/22 SentinelOne reports Q3 ARR up 106% to $487.4M 11/30/22 SentinelOne falls -10.9% RPD Rapid7 $53.38 / +1.88 (+3.65%) 02/01/23 Rapid7 trading resumes 02/01/23 Rapid7 trading halted, volatility trading pause 09/22/22 Rapid7 enters multi-year partnership with The Bruins NYT New York Times $40.60 / -0.54 (-1.31%) 02/08/23 New York Times sees Q1 subscription revenue up 6%-9% 12/12/22 New York Times CFO Roland Caputo to retire 11/02/22 New York Times sees Q4 subscription revenues up 17%-20% 08/11/22 New York Times jumps after ValueAct discloses 6.7% active stake KPRX Kiora Pharmaceuticals $6.82 / -0.1 (-1.45%) 02/09/23 Kiora Pharmaceuticals received IND approval for Phase 2 study of KIO-101 01/03/23 Kiora Pharmaceuticals completes enrollment in PCED study for KIO-201 10/18/22 Kiora Pharmaceuticals Inc trading resumes 10/18/22 Kiora Pharmaceuticals Inc trading halted, volatility trading pause JPM JPMorgan $142.49 / -0.19 (-0.13%) 02/08/23 Chase to hire over 500 small business bankers through 2024 01/20/23 JPMorgan Asset Management receives approval for 100% ownership of China JV 01/13/23 JPMorgan says continues to expect 17% ROTCE in 2023 01/13/23 JPMorgan says targeting potential $12B in share buybacks in 2023 HIMS Hims & Hers $9.55 / +1.12 (+13.29%) 12/05/22 Hims & Hers names Scott Knoer as 1st Chief Pharmacy & Innovation Officer 11/15/22 Amazon announces 'Amazon Clinic' virtual health service 11/08/22 Hims & Hers rises 26.0% 11/08/22 Hims & Hers rises 20.1% EMKR Emcore $1.35 / +0.035 (+2.66%) 12/15/22 Emcore announces sale, leaseback of Tinley Park facility 12/06/22 Emcore introduces new TAC-450 Inertial Measurement Units 09/15/22 Emcore to showcase product portfolio at ION GNSS+ DRCT Direct Digital $5.83 / +0.04 (+0.69%) 08/22/22 Direct Digital appoints Maria Vilchez as Chief Growth Officer DKNG DraftKings $17.73 / +0.06 (+0.34%) 01/31/23 Nevada reports December statewide gaming win up 14.3% to $1.31B 01/30/23 Bragg Gaming launches new content with DraftKings in New Jersey 12/30/22 DraftKings to launch online sportsbook in Ohio on New Year's Day 12/29/22 Cathie Wood's ARK Investment bought 137K shares of DraftKings today CRNC Cerence $30.32 / +1.43 (+4.95%) 02/07/23 Cerence enhances driving experience for Mercedes-Benz tour guide feature 01/09/23 Cerence announces BYD to deploy its conversational AI in BYD EVs worldwide 01/04/23 Cerence announces continued strategic partnership with what3words 12/14/22 Cerence enters partnerships with iHeartMedia, Radioline CPNG Coupang $16.74 / +0.4 (+2.45%) 12/05/22 Coupang director sells $7.47M in common stock 12/05/22 Coupang falls -7.4% 11/09/22 Coupang reports Q3 active customers up 7% y/y BAC Bank of America $36.16 / -0.355 (-0.97%) 02/08/23 BofA to offer residential EV charger financing alongside auto loans 02/06/23 Bank of America exec Koder sells 214,745 common shares 01/13/23 Bank of America sees mid-single digit loan growth next year 01/13/23 Bank of America sees Q1 NII around $14.4B AFRM Affirm $13.05 / -2.94 (-18.39%) 02/08/23 Affirm sinks 18% to $13.02 after Q2 miss, outlook reduction 02/08/23 Affirm cuts 2023 outlook amid macroeconomic headwinds 02/08/23 Affirm sees $77M-$83M in annualized cost savings 02/08/23 Affirm to reduce workforce by 19%, effective today ACCD Accolade $12.50 / -0.1 (-0.79%) 02/06/23 Cathie Wood's ARK Investment bought 313.7K shares of Accolade today NYT RPD DKNG HIMS ACCD EMKR CRNC KPRX BAC JPM AFRM CPNG S SPWR DRCT VERX NYT New York Times $40.60 / -0.54 (-1.31%) 02/09/23 Morgan Stanley New York Times price target raised to $40 from $37 at Morgan Stanley 02/09/23 Barclays New York Times upgraded to Equal Weight from Underweight at Barclays 12/16/22 Morgan Stanley New York Times downgraded to Equal Weight from Overweight at Morgan Stanley 08/11/22 New York Times share buys at UBS flagged by Gordon Haskett on activist link RPD Rapid7 $53.38 / +1.88 (+3.65%) 02/09/23 Canaccord Rapid7 downgraded to Hold at Canaccord on 'soft' 2023 outlook 02/09/23 Mizuho Rapid7 price target raised to $45 from $40 at Mizuho 02/09/23 Baird Rapid7 price target lowered to $56 from $58 at Baird 02/09/23 Raymond James Rapid7 price target raised to $55 from $50 at Raymond James DKNG DraftKings $17.73 / +0.06 (+0.34%) 02/09/23 Roth MKM Roth MKM downgrades DraftKings to Sell with $15 price target 02/09/23 Roth MKM DraftKings downgraded to Sell from Neutral at Roth MKM 02/01/23 Piper Sandler DraftKings layoffs should be viewed positively, says Piper Sandler 01/23/23 Stifel DraftKings initiated with a Hold at Stifel HIMS Hims & Hers $9.55 / +1.12 (+13.29%) 02/09/23 Jefferies Hims & Hers upgraded to Buy at Jefferies ahead of FY23 guidance 02/09/23 Jefferies Hims & Hers upgraded to Buy from Hold at Jefferies 01/10/23 Tigress Financial Hims & Hers price target raised to $12 from $11 at Tigress Financial 01/03/23 Piper Sandler Hims & Hers price target raised to $7 from $6 at Piper Sandler ACCD Accolade $12.50 / -0.1 (-0.79%) 02/09/23 Jefferies Accolade downgraded to Hold at Jefferies after 'lukewarm' survey results 02/09/23 Jefferies Accolade downgraded to Hold from Buy at Jefferies 02/02/23 Raymond James Accolade initiated with an Outperform at Raymond James 02/01/23 Raymond James Accolade initiated with an Outperform at Raymond James EMKR Emcore $1.35 / +0.035 (+2.66%) 02/09/23 Northland Emcore upgraded to Outperform at Northland on potential cable optics sale 02/09/23 Lake Street Emcore upgraded to Buy at Lake Street with CATV business at bottom 02/09/23 Lake Street Emcore upgraded to Buy from Hold at Lake Street 02/09/23 Northland Emcore upgraded to Outperform from Market Perform at Northland CRNC Cerence $30.32 / +1.43 (+4.95%) 02/09/23 Craig-Hallum Craig-Hallum upgrades Cerence to Buy, ups price target to $40 02/09/23 Craig-Hallum Cerence upgraded to Buy from Hold at Craig-Hallum 02/09/23 Wells Fargo Cerence price target raised to $32 from $25 at Wells Fargo 02/09/23 Baird Cerence price target raised to $30 from $23 at Baird KPRX Kiora Pharmaceuticals $6.82 / -0.1 (-1.45%) 02/09/23 Maxim Kiora Pharmaceuticals upgraded to Buy at Maxim after IND approval for KIO-101 02/09/23 Maxim Kiora Pharmaceuticals upgraded to Buy from Hold at Maxim 02/07/23 Ladenburg Ladenburg reiterates Buy on Kiora following Phase 2 KIO-101 OPRA+ IND clearance 01/03/23 Ladenburg Kiora Pharmaceuticals completes enrollment in Phase 2 study, says Ladenburg BAC Bank of America $36.16 / -0.355 (-0.97%) 02/08/23 Keefe Bruyette Keefe Bruyette downgrades 'vulnerable' Bank of America to Underperform 02/08/23 Keefe Bruyette Bank of America downgraded to Underperform at Keefe Bruyette 01/31/23 Atlantic Equities Bank of America downgraded to Neutral from Overweight at Atlantic Equities 01/24/23 BofA Banks' potential new online wallet unlikely to threaten PayPal, says BofA JPM JPMorgan $142.49 / -0.19 (-0.13%) 01/17/23 Citi JPMorgan price target raised to $165 from $150 at Citi 01/17/23 Piper Sandler JPMorgan price target raised to $157 from $150 at Piper Sandler AFRM Affirm $13.05 / -2.94 (-18.39%) 02/09/23 Deutsche Bank Affirm price target lowered to $12 from $18 at Deutsche Bank 02/09/23 DA Davidson Affirm price target lowered to $20 from $24 at DA Davidson 02/09/23 RBC Capital RBC Capital cuts Affirm to Sector Perform on higher funding costs, slower sales 02/09/23 Truist Affirm price target lowered to $17 from $21 at Truist CPNG Coupang $16.74 / +0.4 (+2.45%) 02/09/23 Barclays Coupang initiated with an Overweight at Barclays 12/01/22 New Street Coupang initiated with a Buy at New Street 11/29/22 Bernstein Coupang not gaining market share fast enough, says Bernstein 10/07/22 HSBC Coupang initiated with a Buy at HSBC S SentinelOne $16.20 / +0.455 (+2.89%) 02/09/23 Canaccord Canaccord starts 'long-term secular winner' SentinelOne with Buy 02/09/23 Canaccord SentinelOne initiated with a Buy at Canaccord 01/24/23 JPMorgan SentinelOne initiated with an Overweight at JPMorgan 01/23/23 Guggenheim SentinelOne initiated with a Buy at Guggenheim SPWR SunPower $16.04 / -0.225 (-1.38%) 02/09/23 Janney Montgomery Scott Janney starts SunPower at Neutral with $16 fair value estimate 02/09/23 Janney Montgomery Scott SunPower initiated with a Neutral at Janney Montgomery Scott 01/25/23 Barclays SunPower downgraded to Underweight from Equal Weight at Barclays 01/17/23 Deutsche Bank SunPower price target raised to $21 from $16 at Deutsche Bank DRCT Direct Digital $5.83 / +0.04 (+0.69%) 02/09/23 EF Hutton Direct Digital initiated with a Buy at EF Hutton 07/12/22 Noble Capital Direct Digital initiated with an Outperform at Noble Capital 03/28/22 Roth MKM Direct Digital initiated with a Buy at Roth Capital 03/08/22 Benchmark Benchmark starts 'unique asset' in ad-tech Direct Digital at Buy VERX Vertex $14.90 / +0.51 (+3.54%) 02/09/23 Raymond James Vertex initiated with an Outperform at Raymond James 02/08/23 Raymond James Vertex initiated with an Outperform at Raymond James 01/05/23 Jefferies Vertex downgraded to Hold from Buy at Jefferies 10/21/22 Citi Vertex price target raised to $16 from $15 at Citi VERX SPWR S RPD NYT JPM HIMS EMKR DRCT DKNG CRNC CPNG BAC AFRM ACCD VERX Vertex $14.90 / +0.51 (+3.54%) 11/09/22 Vertex sees Q4 revenue $124M-$127M, consensus $125.19M 11/09/22 Vertex sees FY22 revenue $484.5M-$487.5M, consensus $482.11M 11/09/22 Vertex reports Q3 non-GAAP EPS 8c, consensus 6c SPWR SunPower $16.04 / -0.225 (-1.38%) 11/08/22 SunPower backs FY22 adjusted EBITDA view $90M-$110M 11/08/22 SunPower reports Q3 adjusted cont ops EPS 13c, consensus 8c S SentinelOne $16.20 / +0.455 (+2.89%) 12/06/22 SentinelOne sees FY23 revenue $420M-$421M, consensus $416.3M 12/06/22 SentinelOne sees Q4 revenue $125M, consensus $124.6M 12/06/22 SentinelOne reports Q3 EPS (35c), consensus (22c) 12/06/22 Notable companies reporting after market close RPD Rapid7 $53.38 / +1.88 (+3.65%) 02/08/23 Rapid7 guides initial FY23 EPS 81c-88c, consensus 49c 02/08/23 Rapid7 sees Q1 EPS 7c-10c, consensus 7c 02/08/23 Rapid7 reports Q4 EPS 35c, consensus 18c 11/02/22 Rapid7 sees FY22 EPS 17c-20c, consensus 11c NYT New York Times $40.60 / -0.54 (-1.31%) 02/08/23 New York Times reports Q4 adjusted EPS 59c, consensus 43c 11/02/22 New York Times reports Q3 adjusted EPS 21c, consensus 13c JPM JPMorgan $142.49 / -0.19 (-0.13%) 01/13/23 JPMorgan reports Q4 EPS $3.57, consensus $3.07 10/14/22 JPMorgan reports Q3 EPS $3.12, consensus $2.88 HIMS Hims & Hers $9.55 / +1.12 (+13.29%) 11/07/22 Hims & Hers raises FY22 revenue view $519M-$522M from $470M-$485M 11/07/22 Hims & Hers sees Q4 revenue $159M-$162M, consensus $134.3M 11/07/22 Hims & Hers reports Q3 EPS (9c), consensus (10c) EMKR Emcore $1.35 / +0.035 (+2.66%) 02/08/23 Emcore sees Q2 revenue $$27M$29M, two-estimates $27.5M 02/08/23 Emcore reports Q1 EPS (22c), two-estimates (21c) 12/21/22 Emcore sees Q1 revenue $25M-$27M, consensus $30.86M 12/21/22 Emcore reports Q4 adjusted EPS (29c), consensus (17c) DRCT Direct Digital $5.83 / +0.04 (+0.69%) 11/10/22 Direct Digital raises FY22 revenue view to $85M-$90M from $70M-$75M 11/10/22 Direct Digital reports Q3 EPS 6c, consensus 5c 08/11/22 Direct Digital raises FY22 revenue view to $70M-$75M, consensus $51.9M 08/11/22 Direct Digital reports Q2 EPS 18c, consensus 6c DKNG DraftKings $17.73 / +0.06 (+0.34%) 11/04/22 DraftKings sees 2023 revenue $2.8B-$3B, consensus $2.83B 11/04/22 DraftKings raises 2022 revenue view $2.16B-$2.19B from $2.08B-$2.18B 11/04/22 DraftKings reports Q3 revenue $502M, consensus $437.23M 11/03/22 Notable companies reporting before tomorrow's open CRNC Cerence $30.32 / +1.43 (+4.95%) 02/08/23 Cerence sees FY23 revenue $275M-$290M, consensus $280.71M 02/08/23 Cerence sees Q2 revenue $64M-$68M, consensus $68.25M 02/08/23 Cerence reports Q1 EPS adjusted 36c, consensus 9c 11/29/22 Cerence targets FY24 revenue of $385M, FY26 revenue of $515M CPNG Coupang $16.74 / +0.4 (+2.45%) 11/09/22 Coupang reports Q3 EPS 5c, consensus (3c) 08/10/22 Coupang raises FY22 adjusted EBITDA view 08/10/22 Coupang reports Q2 EPS (4c), consensus (11c) BAC Bank of America $36.16 / -0.355 (-0.97%) 01/13/23 Bank of America reports Q4 EPS 85c, consensus 77c 01/12/23 Notable companies reporting before tomorrow's open 10/17/22 Bank of America reports Q3 EPS 81c, consensus 77c AFRM Affirm $13.05 / -2.94 (-18.39%) 02/08/23 Affirm sees FY23 revenue $1.475B-$1.55B, consensus $1.64B 02/08/23 Affirm sees Q3 revenue $360M-$380M, consensus $417.96M 02/08/23 Affirm reports Q2 EPS ($1.10), consensus (98c) 02/08/23 Notable companies reporting after market close ACCD Accolade $12.50 / -0.1 (-0.79%) 01/09/23 Accolade guides initial FY24 revenue around $410M, consensus $405.4M 01/09/23 Accolade narrows FY23 revenue view to $361M-$365M, consensus $359.2M 01/09/23 Accolade sees Q4 revenue $97M-$101M, consensus $101.7M 01/09/23 Accolade reports Q3 EPS (56c), consensus (62c) 18 Nov 11 Feb SPWR RPD NYT JPM DKNG CPNG BAC AFRM SPWR SunPower $16.04 / -0.225 (-1.38%) 12/02/22 Chinese solar producers dodged U.S. tariffs, WSJ reports 08/31/22 SunPower faces class-action suit over wage theft, SV Biz Journal reports RPD Rapid7 $53.38 / +1.88 (+3.65%) 02/01/23 Cybersecurity company Rapid7 explores sale, Reuters reports 02/01/23 Rapid7 exploring possible sale after attracting interest, Reuters report 02/01/23 Rapid7 exploring sale with help of advisers, Reuters reports NYT New York Times $40.60 / -0.54 (-1.31%) 12/16/22 Twitter suspends journalists covering Musk, company, NBC News reports 12/09/22 New York Times staffers went on strike Thursday, WSJ reports 10/20/22 New York Times halts plans for children's app, WSJ reports 09/13/22 Union members of New York Times, NBC News defy return-to-office, WSJ reports JPM JPMorgan $142.49 / -0.19 (-0.13%) 01/30/23 JPMorgan reviewing oversight of traders, Reuters reports 01/26/23 Stripe planning to go public in next year or make deal, The Information says 01/23/23 JPMorgan files lawsuit against Frank, NY Times reports DKNG DraftKings $17.73 / +0.06 (+0.34%) 02/01/23 DraftKings confirms laying off around 140 employees, iGaming NEXT reports 01/27/23 Molson Coors to team up with DraftKings for Super Bowl commercial buzz, WSJ says 01/19/23 Bally's, FanDuel approved for Massachusetts sports betting licenses, Speros says 11/21/22 Some DraftKings users report being hacked, Action Network reports CPNG Coupang $16.74 / +0.4 (+2.45%) 09/13/22 Coupang denies plans sell food delivery platform, Korea Times reports BAC Bank of America $36.16 / -0.355 (-0.97%) 01/23/23 Banks teaming up to launch digital wallet to compete with PayPal, WSJ reports 01/17/23 Hsu says some big banks could face breakup, WSJ reports 12/17/22 Amazon, Google among Barron's 10 favorite stocks for 2023 12/09/22 BofA CEO Moynihan on short list to replace Yellen, Gaparino says via Twitter AFRM Affirm $13.05 / -2.94 (-18.39%) 12/08/22 Walmart to back Buy-Now-Pay-Later loan fintech venture, The Information reports 09/15/22 CFPB to begin regulating 'buy-now, pay-later' firms, Reuters reports 09/14/22 Walmart-backed One to test checking accounts for workers, shoppers, Reuters says 08/13/22 Affirm CEO says next recession will silence doubters, WSJ reports VERX SPWR S RPD NYT JPM HIMS EMKR DKNG CRNC CPNG BAC AFRM ACCD VERX Vertex $14.90 / +0.51 (+3.54%) 01/05/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations SPWR SunPower $16.04 / -0.225 (-1.38%) 01/30/23 Here's what Wall St. experts are saying about these automakers ahead of earnings 01/30/23 What You Missed This Week in EVs and Clean Energy 01/09/23 What You Missed This Week in EVs and Clean Energy S SentinelOne $16.20 / +0.455 (+2.89%) 01/12/23 What You Missed On Wall Street On Thursday 01/12/23 What You Missed On Wall Street This Morning RPD Rapid7 $53.38 / +1.88 (+3.65%) 02/01/23 What You Missed On Wall Street On Wednesday 02/01/23 What You Missed On Wall Street This Morning 01/24/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations NYT New York Times $40.60 / -0.54 (-1.31%) 02/09/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/08/23 What You Missed On Wall Street On Wednesday 02/08/23 What You Missed On Wall Street This Morning 12/16/22 What You Missed On Wall Street On Friday JPM JPMorgan $142.49 / -0.19 (-0.13%) 01/30/23 What You Missed On Wall Street On Monday 01/23/23 What You Missed On Wall Street On Monday 01/23/23 What You Missed On Wall Street This Morning HIMS Hims & Hers $9.55 / +1.12 (+13.29%) 11/08/22 What You Missed On Wall Street On Tuesday 11/08/22 What You Missed On Wall Street This Morning 11/07/22 Fly Intel: After-Hours Movers EMKR Emcore $1.35 / +0.035 (+2.66%) 12/21/22 What You Missed On Wall Street On Wednesday 12/21/22 What You Missed On Wall Street This Morning DKNG DraftKings $17.73 / +0.06 (+0.34%) 02/09/23 Fly Intel: Pre-market Movers 02/03/23 Bet On It: DraftKings layoffs could signal more emphasis on profitability CRNC Cerence $30.32 / +1.43 (+4.95%) 11/29/22 What You Missed On Wall Street On Tuesday 11/29/22 What You Missed On Wall Street This Morning CPNG Coupang $16.74 / +0.4 (+2.45%) 11/09/22 Fly Intel: After-Hours Movers 08/10/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations BAC Bank of America $36.16 / -0.355 (-0.97%) 01/31/23 What You Missed On Wall Street On Tuesday 01/31/23 What You Missed On Wall Street This Morning 01/31/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations AFRM Affirm $13.05 / -2.94 (-18.39%) 02/08/23 Fly Intel: After-Hours Movers 11/29/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations ACCD Accolade $12.50 / -0.1 (-0.79%) 02/02/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 01/10/23 What You Missed On Wall Street On Tuesday 01/10/23 What You Missed On Wall Street This Morning 02/15/23 44th Annual Aerospace/Defense & Industrials Conference 02/28/23 Cybersecurity Bus Tour 03/06/23 Technology Conference 03/12/23 35th Annual Roth Conference 02/15/23 SunPower - SPWR 02/17/23 DraftKings - DKNG 02/27/23 Hims & Hers - HIMS 04/14/23 JPMorgan - JPM 04/18/23 Bank of America - BAC 02/09/23 Cerence, Inc. 02/28/23 Cerence 03/02/23 Rapid7 03/10/23 EMCORE Corporation SPWR S JPM DKNG CPNG BAC AFRM ACCD SPWR SunPower $16.04 / -0.225 (-1.38%) 01/20/23 SunPower put volume heavy and directionally bearish 12/16/22 SunPower call volume above normal and directionally bullish 12/15/22 SunPower put volume heavy and directionally bearish 12/12/22 SunPower put volume heavy and directionally bearish S SentinelOne $16.20 / +0.455 (+2.89%) 01/03/23 SentinelOne call volume above normal and directionally bullish 12/08/22 SentinelOne call volume above normal and directionally bullish 12/06/22 SentinelOne call volume above normal and directionally bullish 08/31/22 SentinelOne options imply 7.5% move in share price post-earnings JPM JPMorgan $142.49 / -0.19 (-0.13%) 01/19/23 JPMorgan put buyer realizes 24% same-day gains 12/05/22 JPMorgan put volume heavy and directionally bearish 11/30/22 JPMorgan put volume heavy and directionally bearish 10/14/22 Early notable gainers among liquid option names on October 14th DKNG DraftKings $17.73 / +0.06 (+0.34%) 02/09/23 Call buyers take the long-shot in DraftKings ahead of Superbowl Sunday 02/08/23 DraftKings call volume above normal and directionally bullish 01/25/23 DraftKings call volume above normal and directionally bullish 01/13/23 DraftKings call volume above normal and directionally bullish CPNG Coupang $16.74 / +0.4 (+2.45%) 12/27/22 Coupang call volume above normal and directionally bullish 11/14/22 Coupang call volume above normal and directionally bullish 10/17/22 Coupang put volume heavy and directionally bearish 10/14/22 Coupang put volume heavy and directionally bearish BAC Bank of America $36.16 / -0.355 (-0.97%) 01/03/23 Bank of America call volume above normal and directionally bullish 12/07/22 Notable open interest changes for December 7th 12/06/22 Notable open interest changes for December 6th 11/07/22 Bank of America call volume above normal and directionally bullish AFRM Affirm $13.05 / -2.94 (-18.39%) 02/08/23 Affirm Holdings options imply 18.3% move in share price post-earnings 01/20/23 Affirm Holdings call volume above normal and directionally bullish 01/19/23 Affirm Holdings put volume heavy and directionally bearish 01/11/23 Affirm Holdings call volume above normal and directionally bullish ACCD Accolade $12.50 / -0.1 (-0.79%) 01/09/23 Accolade options imply 10.9% move in share price post-earnings
Upgrade	Kiora Pharmaceuticals upgraded to Buy at Maxim after IND approval for KIO-101 » 08:18 02/09/23 02/09 08:18 02/09/23 08:18 KPRX Kiora Pharmaceuticals $6.92 / +2.39 (+52.76%) As previously reported,… As previously reported, Maxim analyst Michael Okunewitch upgraded Kiora Pharmaceuticals to Buy from Hold with a $12 price target after the company disclose that it received IND approval to start its Phase 2 study for KIO-101 in the treatment of ocular presentations of autoimmune diseases. Kiora has also continued to address its capital needs to strengthen the balance sheet, most recently putting a $10M equity line in place, the analyst tells investors in a research note. The firm contends that the company should be positioned to unlock value from several events in 2023, including initial data from the Phase 1b for KIO-301 in retinitis pigmentosa and Phase 2 data for KIO-201 in the first half of the year. ShowHide Related Items >><< Company News Street Research KPRX Kiora Pharmaceuticals $6.92 / +2.39 (+52.76%) 02/09/23 Kiora Pharmaceuticals received IND approval for Phase 2 study of KIO-101 01/03/23 Kiora Pharmaceuticals completes enrollment in PCED study for KIO-201 10/18/22 Kiora Pharmaceuticals Inc trading resumes 10/18/22 Kiora Pharmaceuticals Inc trading halted, volatility trading pause KPRX Kiora Pharmaceuticals $6.92 / +2.39 (+52.76%) 02/09/23 Maxim Kiora Pharmaceuticals upgraded to Buy from Hold at Maxim 02/07/23 Ladenburg Ladenburg reiterates Buy on Kiora following Phase 2 KIO-101 OPRA+ IND clearance 01/03/23 Ladenburg Kiora Pharmaceuticals completes enrollment in Phase 2 study, says Ladenburg 08/25/22 Ladenburg Ladenburg starts ophthalmic-focused Kiora with a Buy
Hot Stocks	Kiora Pharmaceuticals received IND approval for Phase 2 study of KIO-101 » 08:15 02/09/23 02/09 08:15 02/09/23 08:15 KPRX Kiora Pharmaceuticals $6.92 / +2.39 (+52.76%) On February 7, 2023,… On February 7, 2023, Kiora Pharmaceuticals issued a press release announcing that it has received investigational new drug application approval for a Phase 2 study of KIO-101 for the treatment of the Ocular Presentation of Rheumatoid Arthritis or other autoimmune diseases, or OPRA+. This study will enroll approximately 120 patients in a multi-center, controlled, randomized, double-masked trial assessing the safety and efficacy of KIO-101 eye drops in patients living with autoimmune disease who have signs and symptoms of ocular surface disease. The study is expected to begin enrolling patients in Australia in the first half of 2023. ShowHide Related Items >><< Company News Street Research KPRX Kiora Pharmaceuticals $6.92 / +2.39 (+52.76%) 01/03/23 Kiora Pharmaceuticals completes enrollment in PCED study for KIO-201 10/18/22 Kiora Pharmaceuticals Inc trading resumes 10/18/22 Kiora Pharmaceuticals Inc trading halted, volatility trading pause 10/13/22 Kiora Pharmaceuticals regains Nasdaq listing compliance KPRX Kiora Pharmaceuticals $6.92 / +2.39 (+52.76%) 02/09/23 Maxim Kiora Pharmaceuticals upgraded to Buy from Hold at Maxim 02/07/23 Ladenburg Ladenburg reiterates Buy on Kiora following Phase 2 KIO-101 OPRA+ IND clearance 01/03/23 Ladenburg Kiora Pharmaceuticals completes enrollment in Phase 2 study, says Ladenburg 08/25/22 Ladenburg Ladenburg starts ophthalmic-focused Kiora with a Buy
Upgrade	Kiora Pharmaceuticals upgraded to Buy from Hold at Maxim » 07:45 02/09/23 02/09 07:45 02/09/23 07:45 KPRX Kiora Pharmaceuticals $6.92 / +2.39 (+52.76%) Maxim analyst Michael… Maxim analyst Michael Okunewitch upgraded Kiora Pharmaceuticals to Buy from Hold with a $12 price target. ShowHide Related Items >><< Company News Street Research KPRX Kiora Pharmaceuticals $6.92 / +2.39 (+52.76%) 01/03/23 Kiora Pharmaceuticals completes enrollment in PCED study for KIO-201 10/18/22 Kiora Pharmaceuticals Inc trading resumes 10/18/22 Kiora Pharmaceuticals Inc trading halted, volatility trading pause 10/13/22 Kiora Pharmaceuticals regains Nasdaq listing compliance KPRX Kiora Pharmaceuticals $6.92 / +2.39 (+52.76%) 02/07/23 Ladenburg Ladenburg reiterates Buy on Kiora following Phase 2 KIO-101 OPRA+ IND clearance 01/03/23 Ladenburg Kiora Pharmaceuticals completes enrollment in Phase 2 study, says Ladenburg 08/25/22 Ladenburg Ladenburg starts ophthalmic-focused Kiora with a Buy 08/25/22 Ladenburg Kiora Pharmaceuticals initiated with a Buy at Ladenburg
Recommendations	Ladenburg reiterates Buy on Kiora following Phase 2 KIO-101 OPRA+ IND clearance » 12:58 02/07/23 02/07 12:58 02/07/23 12:58 KPRX Kiora Pharmaceuticals $4.45 / +1.23 (+38.20%) Ladenburg analyst Matthew… Ladenburg analyst Matthew Kaplan reiterates a Buy rating on Kiora Pharmaceuticals with a price target of $119 after the company received IND clearance for KIO-101 to be evaluated in a Phase 2 clinical trial for ocular presentation of rheumatoid arthritis, or OPRA. Kiora is enrolling patients in Australia in the first half of 2023. The company also announced that KIO-201, which is being evaluated in a Phase 2 clinical trial for persistent corneal epithelial defects, has completed enrollment, with topline data expected to be reported in a medical conference in the first half of 2023, the firm highlights. Ladenburg is "encouraged" by the update in the KIO-201 program and look forward to the topline data from the study. ShowHide Related Items >><< Company News Street Research KPRX Kiora Pharmaceuticals $4.45 / +1.23 (+38.20%) 01/03/23 Kiora Pharmaceuticals completes enrollment in PCED study for KIO-201 10/18/22 Kiora Pharmaceuticals Inc trading resumes 10/18/22 Kiora Pharmaceuticals Inc trading halted, volatility trading pause 10/13/22 Kiora Pharmaceuticals regains Nasdaq listing compliance KPRX Kiora Pharmaceuticals $4.45 / +1.23 (+38.20%) 01/03/23 Ladenburg Kiora Pharmaceuticals completes enrollment in Phase 2 study, says Ladenburg 08/25/22 Ladenburg Ladenburg starts ophthalmic-focused Kiora with a Buy 08/25/22 Ladenburg Kiora Pharmaceuticals initiated with a Buy at Ladenburg 08/15/22 Maxim Kiora Pharmaceuticals downgraded to Hold from Buy at Maxim
Syndicate	Kiora Pharmaceuticals files to sell 1.05M shares of common stock for holders 17:23 02/03/23 02/03 17:23 02/03/23 17:23 KPRX Kiora Pharmaceuticals $3.52 / + (+0.00%) ShowHide Related Items >><< Company News Street Research KPRX Kiora Pharmaceuticals $3.52 / + (+0.00%) 01/03/23 Kiora Pharmaceuticals completes enrollment in PCED study for KIO-201 10/18/22 Kiora Pharmaceuticals Inc trading resumes 10/18/22 Kiora Pharmaceuticals Inc trading halted, volatility trading pause 10/13/22 Kiora Pharmaceuticals regains Nasdaq listing compliance KPRX Kiora Pharmaceuticals $3.52 / + (+0.00%) 01/03/23 Ladenburg Kiora Pharmaceuticals completes enrollment in Phase 2 study, says Ladenburg 08/25/22 Ladenburg Ladenburg starts ophthalmic-focused Kiora with a Buy 08/25/22 Ladenburg Kiora Pharmaceuticals initiated with a Buy at Ladenburg 08/15/22 Maxim Kiora Pharmaceuticals downgraded to Hold from Buy at Maxim
Recommendations	Kiora Pharmaceuticals completes enrollment in Phase 2 study, says Ladenburg » 13:17 01/03/23 01/03 13:17 01/03/23 13:17 KPRX Kiora Pharmaceuticals $2.92 / -0.53 (-15.36%) Ladenburg analyst Matthew… Ladenburg analyst Matthew Kaplan reiterated a Buy rating and $119 price target on Kiora Pharmaceuticals shares after the company announced the completion of enrollment in a Phase 2 trial of KIO-201 for persistent corneal epithelial defects. Based on initial study observations, Kiora is planning discussions with the FDA for a Phase 3 registrational study of KIO-201 in PCED, Kaplan tells investors in a research note, adding that he is "encouraged" by the update in the KIO-201 program and awaits topline data from the study. ShowHide Related Items >><< Company News Street Research KPRX Kiora Pharmaceuticals $2.92 / -0.53 (-15.36%) 01/03/23 Kiora Pharmaceuticals completes enrollment in PCED study for KIO-201 10/18/22 Kiora Pharmaceuticals Inc trading resumes 10/18/22 Kiora Pharmaceuticals Inc trading halted, volatility trading pause 10/13/22 Kiora Pharmaceuticals regains Nasdaq listing compliance KPRX Kiora Pharmaceuticals $2.92 / -0.53 (-15.36%) 08/25/22 Ladenburg Ladenburg starts ophthalmic-focused Kiora with a Buy 08/25/22 Ladenburg Kiora Pharmaceuticals initiated with a Buy at Ladenburg 08/15/22 Maxim Kiora Pharmaceuticals downgraded to Hold from Buy at Maxim 07/11/22 H.C. Wainwright Kiora Pharmaceuticals price target lowered to $2.50 from $3 at H.C. Wainwright

On The Fly

News and insights, exclusive to thefly.com

10:28	Here's What You Missed in Crypto This Week»
09:38	Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations»
08:59	Fly Intel: Pre-market Movers»
19:09	Fly Intel: After-Hours Movers»
16:33	What You Missed On Wall Street On Thursday»

View all On The Fly Stories »

Upcoming
Events (10)

AUTL ...	Truist Hosted Company Events at 2023 ASCO Annual Meeting
A ...	2023 ASCO Annual Meeting
GERN	Geron
LICY	Li-Cycle
MXL	MaxLinear
	Consumer Retail & Lifestyle Brands
	Healthcare
TERN	Biotechnology--Reception
YJ	Yunji - YJ
WDH	Waterdrop - WDH

View all of today’s events »

Today’s
Syndicate (1)

MKSI	Spot Secondary

View this week’s syndicate »

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial